We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Phase III Trial of Flutiform in COPD Fails Primary Endpoint
Phase III Trial of Flutiform in COPD Fails Primary Endpoint
A Phase III trial of the flutiform inhaler did not meet its primary endpoint of demonstrating statistically significant superiority in the reduction of annualized rates of moderate and severe exacerbations of chronic obstructive pulmonary disease, when compared to mono-component long-acting β2-agonist treatment alone.